Skip to Content

Vorinostat Pregnancy and Breastfeeding Warnings

Vorinostat is also known as: Zolinza

Medically reviewed on August 4, 2017.

Vorinostat Pregnancy Warnings

Vorinostat has been assigned to pregnancy category D by the FDA. Animal studies have revealed that vorinostat crosses the placenta and is found in fetal plasma at levels up to 50% of maternal concentrations. Treatment-related developmental effects including decreased mean live fetal weights, incomplete ossifications of the skull, thoracic vertebra, sternebra, and skeletal variations (cervical ribs, supernumerary ribs, vertebral count, and sacral arch variations), reductions in mean live fetal weight, an elevated incidence of incomplete ossification of the metacarpals, and a dose-related increase in the incidence of malformations of the gall bladder have been reported in animal studies. There are no controlled data in human pregnancy. Vorinostat should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Vorinostat Breastfeeding Warnings

There are no data on the excretion of vorinostat into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from vorinostat, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.

References for breastfeeding information

  1. "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.